EXCLI J EXCLI Journal 1611-2156 Leibniz Research Centre for Working Environment and Human Factors 2017-871 10.17179/excli2017-871 Doc126 Original article N1-benzenesulfonyl-2-pyrazoline hybrids in neurological disorders: Syntheses, biological screening and computational studies Tripathi Avinash C. 1 Upadhyay Savita 1 Paliwal Sarvesh 2 Saraf Shailendra K. * 1 Division of Pharmaceutical Chemistry, Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, Lucknow-226028, U.P., India Professor and Head, Department of Pharmacy, Banasthali Vidyapith, Banasthali, Tonk-304022, Rajasthan, India *To whom correspondence should be addressed: Shailendra K. Saraf, Division of Pharmaceutical Chemistry, Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, BBD City, Faizabad Road, Chinhat, Lucknow-226028, U.P., India; Voice Contact: +91-522-3911052 (office), +919839228022 (mobile), Fax: +91-522-3911152, E-mail: dirpharmniec@gmail.com 19 01 2018 2018 17 126 148 10 10 2017 15 01 2018 Copyright © 2018 Tripathi et al. 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.

 This article is available from http://www.excli.de/vol17/Saraf19012018_proof.pdf

A novel series of 1,3,5-trisubstituted-2-pyrazolines (5a-5t) was prepared via Claisen Schmidt condensation, followed by heterocyclization with hydrazine hydrate, substitution of N1 hydrogen of 2-pyrazoline nucleus with 4-chlorobenzenesulfonylchloride, applying conventional and green chemistry approaches. Among the two, microwave assisted organic synthesis (MAOS) emerged as a better synthetic tool in terms of faster reaction rate and high yield. Various physicochemical and spectral studies were conducted to characterize the synthesized derivatives including- IR, Mass, 1H-NMR, 13C-NMR and elemental analysis. During pharmacological evaluation, compound 5b showed excellent anti-anxiety activity and compound 5k exhibited the best antidepressant effect at the tested doses, 50 and 100 mg/kg b.w., being comparable to diazepam and imipramine, respectively. The docking experiments confirmed the probable mechanism of neuropharmacological action, showing excellent affinity towards MAO-A target protein, which was also evidenced from some of the key interactions with binding site residues Ala68, Tyr69 and Phe352. Furthermore, complimentary in silico pharmacokinetic recital without any potential risk of neurotoxicity (as evaluated by rotarod and actophotometer tests), or carcinogenicity, mutagenicity, reproductive toxicity, acute toxicity and irritancy (as predicted by LAZAR and OSIRIS programs) signified their probable use in depression and anxiety disorders.

 2-Pyrazolines antidepressant and anti-anxiety neurotoxicity microwave synthesis molecular docking in silico ADME prediction Introduction

Monoamine oxidase (MAO) regulates monoaminergic homeostasis and neurotransmission in the nervous system. Low level of certain neurotransmitters (NTs) in the brain, like dopamine (DA), norepinephrine (NE), serotonin (5-HT), and gamma amino butyric acid (GABA), is the main cause of depressive mental disorders. These NTs are released during neurotransmission and are degraded by the MAOs enzymes. Monoamine oxidase inhibitors (MAOIs) block the action of MAOs, and thus increase the concentration of NTs in the brain (Mitoma and Ito, 1992[26]; Meyer et al., 2006[24]). The antidepressant effect of a hydrazine based anti-tubercular drug, iproniazid (a structural analog of isoniazid) started the journey of development of MAOIs. This discovery showed the way to design and produce some more effective analogs such as phenelzine (Zeller and Barsky, 1952[46]). MAOIs belong to the first generation antidepressants used for decades to treat the patients suffering from high level of anxiety, atypical depression (Pletscher, 1991[32]), anergic bipolar depression and treatment resistant depression (Thase, 2012[39]), specific phobias, post-traumatic stress disorder and migraine headaches resistant to other therapies (Gareri et al., 2000[11]). Two major therapeutic categories of MAOI: the MAO-A inhibitors in certain mental disorders such as depression and anxiety (Amrein et al., 1999[2]) and MAO-B inhibitors proved their remedial value in neurodegenerative diseases (Youdim et al., 2006[45]; Foley et al., 2000[10]) including Parkinson's (Cesura and Pletscher, 1992[5]) and Alzheimer's (Volz and Gleiter, 1998[43]). The initial hydrazine class of MAO inhibitors was associated with some severe adverse effects such as liver toxicity and cheese reaction (Brown et al., 1989[4]). These side-effects were correlated to nonselective and irreversible MAO inhibition. These findings prompted research to develop selective and reversible type of MAO (A and B) inhibitors. Pyrazoline derivatives have attracted substantial attention for years, chiefly 1,3,5-trisubstituted-2-pyrazoline pharmacophore is allied with encouraging neurological activities such as tranquilizer, anticonvulsant and antidepressant (Kaplancikli et al., 2010[17]; Ozdemir et al., 2008[28]; Palaska et al., 2001[29]; Rajendra Prasad et al., 2005[35]; Ruhoglu et al., 2005[36]), psychoanaleptic, MAO inhibitory and other biological activities (Chimenti et al., 2004[6]; 2010[7]; Gokhan et al., 2003[13]; Gokhan-Kelekci et al., 2009[14]; Jagrat et al., 2011[15]; Jayaprakash et al., 2008[16]; Karuppasamy et al., 2010[18]; Maccioni et al., 2010[22]; Manna et al., 2002[23]; Mishra and Sasmal, 2011[25]; Sahoo et al., 2010[37]; Agrawal et al., 2012[1]; Gautam et al., 2010[12]). Considering these facts, some 1,3,5-trisubstituted-2-pyrazolines were synthesized by integrating some novel aromatic and hetero-aromatic substitutions at 3rd and 5th positions, respectively. Microwave facilitated synthetic technique was also utilized to prepare the proposed compounds and the results were compared to that of the conventional heating methods (Lidstrom et al., 2001[20]). This work is in continuation to the previous communications by our group (Tripathi et al., 2016[40], Upadhyay et al., 2017[41]; Bhandari et al., 2013[3]) with some novel derivatives having promising potential in the field.

 Materials and Methods

S. D. Fine Chemicals and Sigma Aldrich, Mumbai, India supplied the chemicals and reagents for synthesis and the pre-coated TLC sheets were obtained from Merck Chemicals, India and were used as such. Microwave assisted organic synthesis (MAOS) was performed on Raga's Scientific Microwave System (Ragatech, Pune, Maharashtra, India).

Chemistry

The reaction of suitably substituted aromatic/heteroaromatic ketones with different aldehydes, in alkaline medium, yielded substituted chalcones (1a-1t) via Claisen-Schmidt condensation. Then, the formed chalcones were reacted with hydrazine hydrate (in excess) to give 2-pyrazoline derivatives (2a-2t). Finally, the N1 hydrogen of the 2-pyrazoline nucleus was replaced with 4-chlorobenzenesulfonylchloride (5a-5t), as given in Figure 1(Fig. 1). The reaction progress was examined by thin layer chromatography (TLC), using pre-coated silica gel G plates as stationary phase and iodine vapors/UV light as the visualizing agents.

Synthesis of chalcone derivatives (1a-1t)

The proposed chalcone derivatives of the first step were synthesized by reacting suitably substituted aldehydes and ketones, in equimolar ratio, via conventional and microwave assisted organic synthesis (MAOS) procedures (Tripathi et al., 2016[40]; Upadhyay et al., 2017[41]; Agrawal et al., 2012[1]; Gautam et al., 2010[12]).

Synthesis of 3,5-disubstituted-2-pyrazoline derivatives(2a-2t)

The 3,5-disubstituted-2-pyrazoline derivatives of the second step were synthesized by reacting different chalcone derivatives of the first step with hydrazine hydrate (excess), using conventional and MAOS procedures (Tripathi et al., 2016[40]; Upadhyay et al., 2017[41]).

Synthesis of 1,3,5-trisubstituted-2-pyrazoline derivatives (5a-5t)

Conventional synthesis: Appropriately substituted 2-pyrazoline derivatives (0.001M) of the second step reacted with 4-chlorobenzenesulfonylchloride (0.002M) by stirring, using THF (10 mL) as the solvent. Continued the stirring for 1-4 hrs, poured the reaction mixture in a petri plate and evaporated the solvent up to dryness. Re-precipitated the crude product using acetonitrile/methanol and re-crystallized from acetonitrile/methanol to obtain the pure product (Upadhyay et al., 2017[41]).

MAOS: Appropriately substituted 3,5-disubstituted-2-pyrazolines (0.001M) were reacted with 4-chlorobenzenesulfonylchloride (0.002M) under microwave irradiation (MWI: 210-350W; 80-280s), taking THF (10 mL) as the solvent. The reaction mixture was poured in a petri plate and evaporated the solvent up to dryness. The crude product was re-precipitated using acetonitrile/methanol and recrystallized from acetonitrile/methanol to get the purified derivative (Upadhyay et al., 2017[41]).

Characterization of the synthesized 1,3,5-trisubstituted-2-pyrazoline derivatives

First and second step intermediate compounds were characterized by TLC, melting point (determined by open capillary method and are uncorrected) and mass spectrometric techniques. However, comprehensive physicochemical (Table 1(Tab. 1)) and spectral characterization was undertaken for the final derivatives and the values were found to be in agreement.

4-[1-(4-Chloro-benzenesulfonyl)-5-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-phenol (5a)

IR spectra were recorded on Bruker FT-IR, ALPHA-T (Eco-ATR) spectrophotometers, (Bruker Corporation., USA) and the values are expressed in cm-1. 3220 (N-H stretch), 2865 (C-H Aromatic), 1650 (C=N stretch), 1515 (C-H deform), 1159, 1350 (sym., asym S(=O)2 stretch). 1H-NMR and 13C-NMR spectra were recorded on Bruker Avance-400, FTNMR spectrometer (Bruker, Tech. Pvt. Ltd., USA) at 400MHz and the chemical shifts are reported in parts per million (δ value), taking TMS (δ 0 ppm for 1H NMR) as the internal standard: 2.03-2.09 (dd, Jab: 16.77 Hz, Jax: 3.58 Hz, 1H, Ha), 2.73-2.78 (dd, Jab: 3.85 Hz, Jbx: 17.11 Hz, 1H, Hb), 3.81-3.93 (dd, Jax: 3.50 Hz, Jbx: 17.05 Hz, 1H, Hx), 3.97-4.10 (m, 6H, methyl), 5.23-5.25 (s, 1H, Ar-OH), 6.56-7.90 (m, 11H, Ar). 13C NMR (DMSO, ppm): 37.9 (CH2 pyrazoline), 43.0 (CH pyrazoline), 113.8-146.3 (12CH benzene), 147.5-159.2 (7C benzene), 160.1 (C pyrazoline). Mass spectra were recorded on Waters UPLC-TQD Mass Spectrometer instrument (Waters Corporation, USA) using LC-ESI or APCI-MS Technique; MS (m/z): 473 (M+, 100 %). Elemental analysis was performed on Perkin Elmer-2400, Series-II Analyzer (Waltham, Massachusetts, USA). Anal. Calcd. for C23H21ClN2O5S: C, 58.41; H, 4.48; N, 5.92. Found: C, 58.39; H, 4.50; N, 5.89.

4-[1-(4-Chloro-benzenesulfonyl)-5-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-phenol (5b)

IR (cm-1): 3359 (N-H stretch), 3142 (C-H Aromatic), 1606 (C=N stretch), 1516 (C-H deform), 1165, 1351 (sym., asym S(=O)2 stretch). 1H-NMR ( δ ppm, DMSO): 1.98-1.99 (dd, Jab: 17.12 Hz, Jax: 3.41 Hz, 1H, Ha), 3.40-3.48 (dd, Jab: 4.01 Hz, Jbx: 16.23 Hz, 1H, Hb), 3.70-3.80 (dd, Jax: 3.28 Hz, Jbx: 17.46 Hz, 1H, Hx), 5.39-5.45 (s, 1H, Ar-OH), 6.88-7.89 (m, 12H, Ar). 13C NMR (DMSO, ppm): 38.6 (CH2 pyrazoline), 43.2 (CH pyrazoline), 115.6-140.3 (12CH benzene), 158.3-160.1 (3C benzene), 161.2 (C pyrazoline). MS (m/z): 447 (M+, 100 %). Anal. Calcd. for C21H16Cl2N2O3S: C, 56.38; H, 3.61; N, 6.26. Found: C, 57.42; H, 3.59; N, 6.24.

4-[1-(4-Chloro-benzenesulfonyl)-5-furan-2-yl-4,5-dihydro-1H-pyrazol-3-yl]-phenol (5c)

IR (cm-1): 3472 (N-H stretch), 3239 (C-H Aromatic), 1602 (C=N stretch), 1434 (C-H deform), 1159, 1348 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 2.14-2.16 (dd, Jab: 17.00 Hz, Jax: 3.18 Hz, 1H, Ha), 3.27-3.36 (dd, Jab: 3.88 Hz, Jbx: 16.69 Hz, 1H, Hb), 3.42-3.84 (dd, Jax: 3.05 Hz, Jbx: 16.96 Hz, 1H, Hx), 5.20 (s, 1H, Ar-OH), 6.04-7.66 (m, 11H, Ar). 13C NMR (DMSO, ppm): 40.1 (CH2 pyrazoline), 44.5 (CH pyrazoline), 104.2-142.9 (11CH Ar), 135.3-158.6 (4C benzene), 159.0 (C furan), 160.7 (C pyrazoline). MS (m/z): 229 (M+, 100 %). Anal. Calcd. for C19H15ClN2O4S: C, 56.65; H, 3.75; N, 6.95. Found: C, 56.66; H, 3.77; N, 6.93.

4-[1-(4-Chloro-benzenesulfonyl)-5-thiophen-2-yl-4,5-dihydro-1H-pyrazol-3-yl]-phenol (5d)

IR (cm-1): 3270 (N-H stretch), 3010 (C-H Aromatic), 1615 (C=N stretch), 1463 (C-H deform), 1189, 1382 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 1.99-2.00 (dd, Jab: 15.72 Hz, Jax: 3.86 Hz, 1H, Ha), 3.40-3.48 (dd, Jab: 3.94 Hz, Jbx: 16.70 Hz, 1H, Hb), 3.71-3.85 (dd, Jax: 3.28 Hz, Jbx: 17.46 Hz, 1H, Hx), 5.45 (s, 1H, Ar-OH), 6.75-7.80 (m, 11H, Ar). 13C NMR (DMSO, ppm): 39.4 (CH2 pyrazoline), 44.8 (CH pyrazoline), 113.8-138.6 (11CH Ar), 120.1-151.7 (4C benzene), 161.3 (C thiophene), 162.4 (C pyrazoline). MS (m/z): 419 (M+, 95 %). Anal. Calcd. for C19H15ClN2O3S2: C, 54.47; H, 3.61; N, 6.69. Found: C, 54.43; H, 3.62; N, 6.67.

1-(4-Chloro-benzenesulfonyl)-3,5-bis-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazole (5f)

IR (cm-1): 3315 (N-H stretch), 3100 (C-H Aromatic), 1616 (C=N stretch), 1465 (C-H deform), sym., asym S(=O)2 stretch (1164, 1389). 1H NMR (δ ppm, DMSO): 1.91-1.96 (dd, Jab: 17.56 Hz, Jax: 3.50 Hz, 1H, Ha), 3.29-3.48 (dd, Jab: 4.01 Hz, Jbx: 17.23 Hz, 1H, Hb), 3.66-3.84 (dd, Jax: 3.75 Hz, Jbx: 16.54 Hz, 1H, Hx), 7.00-7.77 (m, 12H, Ar). 13C NMR (DMSO, ppm): 39.0 (CH2 pyrazoline), 42.5 (CH pyrazoline), 125.8-131.2 (12CH benzene), 136.1-141.9 (4C benzene), 161.2 (C pyrazoline). MS (m/z): 463 (M+, 55 %). Anal. Calcd. for C21H15Cl3N2O2S: C, 54.15; H, 3.25; N, 6.01. Found: C, 54.11; H, 3.22; N, 6.00.

1-(4-Chloro-benzenesulfonyl)-3-(4-chloro-phenyl)-5-furan-2-yl-4,5-dihydro-1H-pyrazole (5g)

IR (cm-1): 3330 (N-H stretch), 3092 (C-H Aromatic), 1685 (C=N stretch), 1539 (C-H deform), 1168, 1355 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 2.08-2.13 (dd, Jab: 15.31 Hz, Jax: 2.98 Hz, 1H, Ha), 3.39-3.44 (dd, Jab: 4.16 Hz, Jbx: 15.57 Hz, 1H, Hb), 3.61-3.79 (dd, Jax: 3.58 Hz, Jbx: 16.95 Hz, 1H, Hx), 6.53-7.60 (m, 11H, Ar). 13C NMR (DMSO, ppm): 39.9 (CH2 pyrazoline), 42.5 (CH pyrazoline), 107.7-128.5 (11CH Ar), 130.2-136.8 (3C benzene), 159.0 (C furan), 161.7 (C pyrazoline). MS (m/z): 421 (M+, 65 %). Anal. Calcd. for C19H14Cl2N2O3S: C, 54.17; H, 3.35; N, 6.65. Found: C, 54.20; H, 3.39; N, 6.61.

1-(4-Chloro-benzenesulfonyl)-3-(4-chloro-phenyl)-5-thiophen-2-yl-4,5-dihydro-1H-pyrazole (5h)

IR (cm-1): 3345 (N-H stretch), 3056 (C-H Aromatic), 1621 (C=N stretch), 1471 (C-H deform), 1165, 1393 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 2.10-2.19 (dd, Jab: 16.88 Hz, Jax: 3.29 Hz, 1H, Ha), 4.15-4.22 (dd, Jab: 4.01 Hz, Jbx: 16.78 Hz, 1H, Hb), 4.20-4.23 (dd, Jax: 3.63 Hz, Jbx: 16.91 Hz, 1H, Hx), 6.65-7.79 (m, 11H, Ar). 13C NMR (DMSO, ppm): 39.7 (CH2 pyrazoline), 41.3 (CH pyrazoline), 121.4-136.5 (11CH Ar), 128.6-134.1 (3C benzene), 139.4 (C thiophene), 155.8 (C pyrazoline). MS (m/z): 437 (M+, 40 %). Anal. Calcd. for C19H14Cl2N2O2S2: C, 52.18; H, 3.23; N, 6.41. Found: C, 52.17; H, 3.20; N, 6.47.

1-(4-Chloro-benzenesulfonyl)-5-(3,4-dimethoxy-phenyl)-3-naphthalen-1-yl-4,5-dihydro-1H-pyrazole (5i)

IR (cm-1): 3345 (N-H stretch), 3056 (C-H Aromatic), 1577 (C=N stretch), 1462 (C-H deform), 116570, 1362 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 1.97-1.98 (dd, Jab: 17.22 Hz, Jax: 3.52 Hz, 1H, Ha), 3.39-3.47 (dd, Jab: 3.87 Hz, Jbx: 16.73 Hz, 1H, Hb), 3.54-3.69 (dd, Jax: 3.18 Hz, Jbx: 17.26 Hz, 1H, Hx), 3.80-3.94 (m, 6H, methyl), 6.78-7.64 (m, 14H, Ar). 13C NMR (DMSO, ppm): 39.7 (CH2 pyrazoline), 42.5 (CH pyrazoline), 61.7 (2CH3), 113.7-132.5 (14CH Ar), 130.8-137.2 (7C Ar), 159.3 (C pyrazoline). MS (m/z): 507 (M+, 50 %). Anal. Calcd. for C27H23ClN2O4S: C, 63.96; H, 4.57; N, 5.53. Found: C, 64.07; H, 4.61; N, 5.46.

1-(4-Chloro-benzenesulfonyl)-5-(4-chloro-phenyl)-3-naphthalen-1-yl-4,5-dihydro-1H-pyrazole (5j)

IR (cm-1): 3266 (N-H stretch), 3011 (C-H Aromatic), 1570 (C=N stretch), 1495 (C-H deform), 1166, 1362 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 2.15-2.19 (dd, Jab: 16.68 Hz, Jax: 3.27 Hz, 1H, Ha), 3.83-3.88 (dd, Jab: 3.95 Hz, Jbx: 17.10 Hz, 1H, Hb), 3.50-3.67 (dd, Jax: 4.12 Hz, Jbx: 16.97 Hz, 1H, Hx), 6.90-7.73 (m, 14H, Ar). 13C NMR (DMSO, ppm): 39.2 (CH2 pyrazoline), 46.4 (CH pyrazoline), 124.2-129.0 (14CH Ar), 128.5-136.1 (7C benzene), 158.7 (C pyrazoline). MS (m/z): 481 (M+, 50 %). Anal. Calcd. for C25H18Cl2N2O2S: C, 62.37; H, 3.77; N, 5.82. Found: C, 62.49; H, 3.80; N, 5.78.

1-(4-Chloro-benzenesulfonyl)-5-furan-2-yl-3-naphthalen-1-yl-4,5-dihydro-1H-pyrazole (5k)

IR (cm-1): 3290 (N-H stretch), 3050 (C-H Aromatic), 1635 (C=N stretch), 1469 (C-H deform), 1166, 1355 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 2.48-2.51 (dd, Jab: 17.12 Hz, Jax: 3.41 Hz, 1H, Ha), 3.04-3.89 (dd, Jab: 4.01 Hz, Jbx: 16.23 Hz, 1H, Hb), 4.88-5.21 (dd, Jax: 3.28 Hz, Jbx: 17.46 Hz, 1H, Hx), 6.80-6.93 (d, 2H, Ar), 7.43-7.54 (m, 4H, Ar), 7.66-7.85 (m, 7H, Ar). 13C NMR (DMSO, ppm): 50.7 (CH2 pyrazoline), 77.2 (CH pyrazoline), 124.4-126.9 (2CH furan), 129.0-131.3 (7CH naphthalene), 133.7-138.2 (4CH benzene), 159.4 (C pyrazoline). MS (m/z): 437 (M+, 50 %), 438 (30 %). Anal. Calcd. for C23H17ClN2O3S: C, 63.23; H, 3.92; N, 6.41. Found: C, 63.26; H, 3.97; N, 6.40.

1-(4-Chloro-benzenesulfonyl)-3-naphthalen-1-yl-5-thiophen-2-yl-4,5-dihydro-1H-pyrazole (5l)

IR (cm-1): 3292 (N-H stretch), 3047 (C-H Aromatic), 1581 (C=N stretch), 1509 (C-H deform), 1177, 1322 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 2.08-2.09 (dd, Jab: 17.48 Hz, Jax: 2.99 Hz, 1H, Ha), 3.10-3.18 (dd, Jab: 3.74 Hz, Jbx: 17.04 Hz, 1H, Hb), 3.83-3.86 (dd, Jax: 3.26 Hz, Jbx: 16.36 Hz, 1H, Hx), 6.60-7.92 (m, 14H, Ar). 13C NMR (DMSO, ppm): 40.6 (CH2 pyrazoline), 46.1 (CH pyrazoline), 118.5-129.2 (14CH Ar), 137.8-148.1 (6C Ar), 161.5 (C pyrazoline). MS (m/z): 463 (M+, 50 %). Anal. Calcd. for C23H17ClN2O2S2: C, 60.98; H, 3.78; N, 6.18. Found: C, 61.06; H, 3.76; N, 6.21.

2-[1-(4-Chloro-benzenesulfonyl)-5-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-pyridine (5q)

IR (cm-1): 3321 (N-H stretch), 3084 (C-H Aromatic), 1624 (C=N stretch), 1466 (C-H deform), 1170, 1337 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 1.89-1.91 (dd, Jab: 15.62 Hz, Jax: 3.17 Hz, 1H, Ha), 3.33-3.39 (dd, Jab: 3.74 Hz, Jbx: 17.11 Hz, 1H, Hb), 3.65-3.80 (dd, Jax: 3.54 Hz, Jbx: 16.91 Hz, 1H, Hx), 3.73-3.94 (m, 6H, methyl), 6.97-8.21 (m, 11H, Ar). 13C NMR (DMSO, ppm): 40.2 (CH2 pyrazoline), 45.7 (CH pyrazoline), 49.5 (6C, CH3), 114.9-135.8 (11CH Ar), 143.4-152.8 (6C benzene), 161.9 (C pyrazoline). MS (m/z): 458 (M+, 30 %). Anal. Calcd. for C22H20ClN3O4S: C, 57.70; H, 4.40; N, 9.18. Found: C, 57.64; H, 4.45; N, 9.14.

2-[1-(4-Chloro-benzenesulfonyl)-5-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-pyridine (5r)

IR (cm-1): 3421 (N-H stretch), 3091 (C-H Aromatic), 1616 (C=N stretch), 1471 (C-H deform), 1170,2 1383 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 1.91-1.94 (dd, Jab: 17.36 Hz, Jax: 3.21 Hz, 1H, Ha), 3.64-3.48 (dd, Jab: 4.12 Hz, Jbx: 17.44 Hz, 1H, Hb), 3.69-3.85 (dd, Jax: 3.28 Hz, Jbx: 16.55 Hz, 1H, Hx), 7.29-8.69 (m, 12H, Ar). 13C NMR (DMSO, ppm): 40.2 (CH2 pyrazoline), 44.5 (CH pyrazoline), 124.6-149.2 (12CH Ar), 137.1-139.4 (2C benzene), 154.2 (C pyridine), 160.7 (C pyrazoline). MS (m/z): 432 (M+, 55%). Anal. Calcd. for C20H15Cl2N3O2S: C, 55.56; H, 3.50; N, 9.72. Found: C, 55.60; H, 3.51; N, 9.68.

2-[1-(4-Chloro-benzenesulfonyl)-5-thiophen-2-yl-4,5-dihydro-1H-pyrazol-3-yl]-pyridine (5t)

IR (cm-1): 3387 (N-H stretch), 3083 (C-H Aromatic), 1612 (C=N stretch), 1468 (C-H deform), 1167, 1389 (sym., asym S(=O)2 stretch). 1H NMR (δ ppm, DMSO): 1.90-1.93 (dd, Jab: 17.23 Hz, Jax: 3.32 Hz, 1H, Ha), 3.46-3.50 (dd, Jab: 3.87 Hz, Jbx: 16.65 Hz, 1H, Hb), 3.82-3.89 (dd, Jax: 3.14 Hz, Jbx: 16.91 Hz, 1H, Hx), 6.53-8.97 (m, 11H, Ar). 13C NMR (DMSO, ppm): 38.6 (CH2 pyrazoline), 43.2 (C pyrazoline), 115.6-140.3 (12CH benzene), 144.9-157.1 (4C Ar), 161.3 (C pyrazoline). MS (m/z): 403 (M+, 25 %). Anal. Calcd. for C18H14ClN3O2S2: C, 53.53; H, 3.49; N, 10.40. Found: C, 53.49; H, 3.53; N, 10.37.

Biological evaluationStudy animals

The study protocols were authenticated by the Institutional Animal Ethics Committee (IAEC) with the protocol number BBDNIIT/IAEC/009/2014.

Animal house, Faculty of Pharmacy, BBDNIIT, Lucknow, U.P., India provided animals (male albino mice) for the in-vivo study which were treated humanely and maintained under standard conditions of temperature (26 ± 2 ºC), percent humidity (55 ± 5), light and dark cycles and free access to food and water.

Study design

The studies were performed as per reported procedures (Tripathi et al., 2016[40]; Upadhyay et al., 2017[41]). The detailed description of the groups and respective doses are given in Table 2(Tab. 2).

Antidepressant activity

The antidepressant potential of the synthesized derivatives (5a-5t) was evaluated using behavioral in vivo tests in mice model, such as forced swim test (FST) and tail suspension test, (TST) as given by Porsolt (1981[33]) and Willner and Mitchell (2002[44]).

Porsolt's behavioral despair or FST

In FST, the state of despair can be minimized by different therapeutically effective antidepressants (Porsolt et al., 1977[34]; Vogel, 2002[42]). The duration of immobility in animals, produced by the test compounds, was measured by known procedures (Tripathi et al., 2016[40]; Upadhyay et al., 2017[41]).

Tail suspension test (TST)

TST is another well known method (Steru et al., 1985[38]; Vogel, 2002[42]), employed to evaluate the antidepressant potential of the test compounds. In this test, the duration of immobility was measured by known procedures (Tripathi et al., 2016[40]; Upadhyay et al., 2017[41]).

Anti-anxiety activity

The maze model was used to evaluate anti-anxiety potential of the test compounds, which selectively identified the anxiolytic (open arm exploration time increased and time spent in closed arms decreased) and anxiogenic drugs (Vogel, 2002[42]).

Elevated plus-maze test

The elevated plus-maze was used to determine anxiety-related behavior, measured by the extent to which the mouse avoids visiting the open arm of the maze (Lister, 1987[21]; Pellow et al., 1985[31]). After one hour of oral administration of the test compound, observations (i.e. time spent in closed arm and total number of the arm entries) were recorded during the 6 minute test duration by known procedures (Tripathi et al., 2016[40]; Upadhyay et al., 2017[41]).

Neurotoxicity study

This study was used to evaluate the effect of the compounds on the CNS, employing various behavioral tests, such as rotarod, open-field/actophotometer, turning on flat surface and inclined plane tests in mice model (Vogel, 2002[42]; Parasuraman, 2011[30]).

Neuromuscular coordination study

The effect of the compounds on motor coordination, where relaxation of skeletal muscle is produced, was examined, as per method given by Dunham and Miya in 1957[9], with slight modification (Vogel et al., 2002[42]).

Locomotor activity (actophotometer test)

Locomotor activities of the animals were used as an index of their mental alertness, which is affected (increased or decreased) by majority of the CNS acting drugs (Dhingra and Goyal, 2008[8]; Tripathi et al., 2016[40]; Upadhyay et al., 2017[41]).

Acute toxicity study

The consequences (changes in skin and fur, behavior patterns, convulsions, tremors and death) of a single dose on a particular animal species was determined by acute toxicity testing. In this study, acute oral toxicity (LD50) of two most active final derivatives (5b and 5k) was performed as per guidelines laid by Organization for Economic Cooperation and Development (OECD) guideline No 423 “Acute Oral Toxicity - Acute Toxic Class Method” using known procedures (OECD, 2001[27]).

Computational studies

Molecular docking simulations were used to predict binding affinity and binding orientations of the synthesized compounds to the MAO-A protein (PDB ID: 2Z5X), with the help of GLIDE program (Schrödinger, LLC, 2014), using known procedures (Tripathi et al., 2016[40]; Upadhyay et al., 2017[41]). QikProp module of Schrödinger software program was successfully employed for in silico prediction of ADME properties of the synthesized derivatives. Furthermore, for in silico toxicity prediction of the synthesized compounds, two freely accessible computer programs (LAZAR and OSIRIS Property explorer) were employed. Among them, LAZAR provided a generic tool for predicting complex toxicological end points (like long-term toxicity, reproductive toxicity and carcinogenicity). OSIRIS program calculated various drug-related properties of chemical structures and risks of untoward effects, which are considered as an indication of drug-conform behavior (Klebe, 2000[19]).

Statistical analysis

Statistical analysis was carried out using Graph Pad Prism 5.0 (Graph Pad Software, San Diego, CA). Experimental results are expressed as mean±SD, analyzed by one-way ANOVA followed by Dunnett's test for the possible significance (P<0.05) between various groups.

 Results and Discussion

A total of fourteen 1,3,5-trisubstituted 2-pyrazoline derivatives (5a-5t) were prepared through Claisen-Schmidt condensation, followed by heterocyclization and substitution with 4-chlorobenzenesulfonylchloride using both, conventional and MAOS methods. The microwave assisted procedures were developed for the first time to synthesize the final 1,3,5-trisubstituted-2-pyrazoline derivatives. The research outcomes suggested that almost all the derivatives synthesized by this technique were obtained at a faster rate and in a better synthetic yield in comparison to conventional procedures. The prepared derivatives were analyzed by various physicochemical (Table 1(Tab. 1)) and spectral techniques and results comply with the proposal. The IR spectra reflect some characteristic absorption bands in the corresponding regions to C=N str (1509-1612 cm-1), N-H str (3449-3107 cm-1) and C-H deform (1431-1354 cm-1). In the third step derivatives, a characteristic peak of sulfonyl group was also observed in the IR spectra. 1H-NMR spectra showed that two dissimilar methylene protons (Ha/Hb) were visible at δ 2.92-3.38 ppm, 3.70-3.93 which coupled themselves and with the methine proton (Hx) at δ 6.67-7.03 in vicinity. The other values were in congruence with the corresponding aliphatic and aromatic protons.

The pharmacological results (Table 2(Tab. 2) and Figure 2(Fig. 2)) demonstrated that number of entries in closed and open arms, in the elevated plus maze test, increased significantly with a lesser closed arm exploration time (Figure 2a and 2b(Fig. 2)) for Compound 5b and Compound 5k showed the best antidepressant action (Figure 2c and 2d(Fig. 2)) in FST and TST models at the evaluated doses. The pharmacological actions of the prepared analogs were observed in a dose dependent manner, as the magnitude of the effects increased at higher tested doses (100 mg/kg b.w.). The structure activity relationship studies established that C-3 naphthalen-1-yl substitution and C-5 furan-2-yl substitution at 2-pyrazoline nucleus were crucial for the antidepressant activity (5k). However, a polar substitution of 4-hydroxyphenyl group at 3rd position (5b) was essential in eliciting anxiolytic activity.

MAOs are considered as an important biological target to develop drugs against certain mental disorders, such as depression and anxiety. It has been also established that the 2-pyrazoline derivatives possess excellent affinity towards MAO isoforms, as reported in previous literatures. Docking studies allowed to gain some structural inputs towards binding characteristics of the prepared derivatives with the MAO-A target protein. The most stable conformation of ligand-protein complex and the interaction studies of the most active compounds, 5b and 5k at the MAO-A protein binding pocket have been depicted in Figure 3(Fig. 3) and 4(Fig. 4). Docking studies inferred that Ala 68, Tyr69 and Phe352 are some important residues interacting at the MAO-A binding pocket. It was evident that at 2-pyrazoline nucleus, N1 p-chlorobenzenesulfonyl substitution proved to be very useful and all the compounds having this substitution showed better activity than the N1 unsubstituted pyrazolines (Tripathi et al., 2016[40]). The presence of sulfonyl group at N1 position of 2-pyrazoline nucleus evidenced H-bonding interaction between sulfonyl oxygen and Ala68 and Tyr69 residues at the MAO-A binding pocket. It was demonstrated in previous works that ligands having such type of hydrogen bond interactions are well placed in the aromatic cage of the MAO protein possessing C5 furyl/ substituted phenyl ring and N1-benzenesulfonyl ring of 2-pyrazoline nucleus. The naphthyl/4-chlorophenyl rings showed, imperative pi-pi stacking interactions with Phe352 backbone residue. It was also evident that most of the interactions of PDB co-crystal ligand 2Z5X were conserved in compounds 5b and 5k. Furthermore, the predicted binding affinity (Glide gscores) of the prepared analogs complemented well with the in vivo anti-anxiety and antidepressant activities data.

The synthesized compounds were also tested for their probable neurotoxicological effects, such as motor coordination (rotarod test) and locomotor activity (actophotometer test). The obtained results suggested that these derivatives were completely free from severe neurotoxicity (motor co-ordinations and locomotor disturbances) threats at the evaluated doses (Table 2(Tab. 2)). In Rotarod test, the mean fall-off time of most of the mice was greater than 180 seconds, and hence these compounds may not affect the motor coordination of the animals. Also, the mean counts in actophotometer test in pre-dose studies, and after 1 hour of dosing, were not significantly different and therefore, any probability of CNS stimulating or depressing effects of the tested compounds was ruled out. Additionally, most potent derivatives were evaluated for their acute toxicity at the corresponding doses. None of them showed any changes in behavioral pattern, convulsions, tremors, skin changes and death throughout the 14 days acute toxicity studies. Also, encouraging in silico pharmacokinetic properties (Table 3(Tab. 3)) were observed. Moreover, the screened compounds were not liable to cause carcinogenicity, mutagenicity, reproductive toxicity, acute toxicity and irritancy. Therefore, they were regarded to be safe as was corroborated by the computational programs such as LAZAR and OSIRIS (Table 4(Tab. 4)).

 Conclusion

This study concludes that the synthesized 2-pyrazoline analogs possess excellent to good antidepressant and anti-anxiety potential, as evaluated using various in vivo methods. The presence of C-3 naphthalen-1-yl substitution and C-5 furan-2-yl substitution at 2-pyrazoline nucleus was decisive for the antidepressant activity (5k). However, a polar substitution of 4-hydroxyphenyl group at 3rd position (5b) was essential in eliciting anxiolytic activity. Nearly all the compounds were completely free from any neurotoxic indications, with a complementary pharmacokinetic behavior as predicted by in silico methods. Molecular docking experiments ascertained some imperative interactions of these compounds with the target protein, playing a pivotal role in neuropharmacology. Thus, in a nutshell, the synthesized 2-pyrazoline derivatives may prove their worth in the treatment and management of certain mental disorders, possibly through MAO-A inhibition.

Acknowledgements

The authors would like to thank Central Drugs Research Institute (CDRI), Lucknow, India and Department of Chemistry, Banasthali Vidyapith University, Banasthali, Rajasthan, India for providing the library and sophisticated analytical instrument facilities. We would extend our sincere gratitude to the All India Council for Technical Education (AICTE), New Delhi, India, for providing grant under the Research Promotion Scheme (Grant No.: 8023/RID/RPS/30 (Pvt.) 2011-12), through which the computational software facility has been made available at the host institute and the technical support team/application scientists of Schrödinger Inc. for their help during implementation of the project.

 Conflict of interest

No conflict of interest is reported by the authors.

 Agrawal M Sonar PK Saraf SK Synthesis of 1,3,5-trisubstituted pyrazoline nucleus containing compounds and screening for antimicrobial activity Med Chem Res 2012 21 3376 3381 Amrein R Martin JR Cameron AM Moclobemide in patients with dementia and depression Adv Neurol 1999 80 509 519 Bhandari S Tripathi AC Saraf SK Synthesis and anticonvulsant activity of some 2-pyrazoline derivatives Med Chem Res 2013 22 5290 5296 Brown CS Kent TA Bryant SG Gevedon RM Campbell JL Felthous AR Blood platelet uptake of serotonin in episodic aggression Psychiatry Res 1989 27 5 12 Cesura AM Pletscher A The new generation of monoamine oxidase inhibitors Prog Drug Res 1992 38 171 297 Chimenti F Bolasco A Manna F Secci D Chimenti P Befani O Synthesis and selective inhibitory activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against monoamine oxidase J Med Chem 2004 47 2071 2074 Chimenti F Carradori S Secci D Bolasco A Bizzarri B Chimenti P Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives Eur J Med Chem 2010 45 800 804 Dhingra D Goyal PK The CNS depressant drugs such as barbiturates and alcohol reduce the motor activity while the stimulants such as caffeine and amphetamines increase the activity Indian J Exp Biol 2008 46 212 218 Dunham NW Miya TS A note on a simple apparatus for detecting neurological deficit in rats and mice J Am Pharm Assoc Am Pharm Assoc 1957 46 208 209 Foley P Gerlach M Youdim MB Riederer P MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord 2000 6 25 47 Gareri P Falconi U De Fazio P De Sarro G Conventional and new antidepressant drugs in the elderly Prog Neurobiol 2000 61 353 396 Gautam V Chawla V Sonar PK Saraf SK Syntheses, characterization and antimicrobial evaluation of Some 1, 3, 5-trisubustituted pyrazole derivatives E-Journal of Chemistry 2010 7 1190 1195 Gokhan N Yesilada A Ucar G Erol K Bilgin AA 1-N-substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: synthesis and evaluation as MAO inhibitors Arch Pharm (Weinheim) 2003 336 362 371 Gokhan-Kelekci N Koyunoglu S Yabanoglu S Yelekci K Ozgen O Ucar G New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity Bioorg Med Chem 2009 7 675 689 Jagrat M Behera J Yabanoglu S Ercan A Ucar G Sinha BN Pyrazoline based MAO inhibitors: Synthesis, biological evaluation and SAR studies Bioorg Med Chem Lett 2011 21 4296 4300 Jayaprakash V Sinha BN Ucar G Ercan A Pyrazoline-based mycobactin analogues as MAO-inhibitors Bioorg Med Chem Lett 2008 18 6362 6368 Kaplancikli ZA Ozdemir A Turan-Zitouni G Altintop MD Can OD New pyrazoline derivatives and their antidepressant activity Eur J Med Chem 2010 45 4383 4387 Karuppasamy M Mahapatra M Yabanoglu S Ucar G Sinha BN Basu A Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies Bioorg Med Chem 2010 18 1875 1881 Klebe G Recent developments in structure-based drug design J Mol Med 2000 78 269–81 Lidstrom P Tierney J Wathey B Westman J Microwave assisted organic synthesis- a review Tetrahedron 2001 57 9225 9283 Lister RG The use of a plus-maze to measure anxiety in the mouse Psychopharmacology (Berl) 1987 92 180 185 Maccioni E Alcaro S Orallo F Cardia C Distinto S Costa G Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase Eur J Med Chem 2010 45 4490 4498 Manna F Chimenti F Bolasco A Secci D Bizzarri B Befani O Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives Bioorg Med Chem Lett 2002 12 3629 3633 Meyer JH Ginovart N Boovariwala A Sagrati S Hussey D Garcia A Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression Arch Gen Psychiatry 2006 63 1209 1216 Mishra N Sasmal D Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation Bioorg Med Chem Lett 2011 21 1969 1973 Mitoma J Ito A Mitochondrial targeting signal of rat liver monoamine oxidase B is located at its carboxy terminus J Biochem 1992 111 20 24 OECD OECD Guidelines for Testing of Chemicals 423: Acute Oral Toxicity - Acute Toxic Class Method 2001 Paris Organization for Economic Corporation and Development Ozdemir Z Kandilci HB Gumusel B Calis U Bilgin AA Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-thienyl)pyrazoline derivatives Arch Pharm (Weinheim) 2008 341 701 707 Palaska E Aytemir M Uzbay IT Erol D Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines Eur J Med Chem 2001 36 539 543 Parasuraman S Toxicological screening J Pharmacol Pharmacother 2011 2 74 79 Pellow S Chopin P File SE Briley M Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat J Neurosci Methods 1985 14 149 167 Pletscher A The discovery of antidepressants: a winding path Experientia 1991 47 4 8 Porsolt RD Antidepressants 1981 New York Raven Press Porsolt RD Bertin A Jalfre M Behavioral despair in mice: a primary screening test for antidepressants Arch Int Pharmacodyn Ther 1977 229 327 336 Rajendra Prasad Y Lakshmana Rao A Prasoona L Murali K Ravi Kumar P Synthesis and antidepressant activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(2''-hydroxy naphthalen-1''-yl)-1,5-diphenyl-2-pyrazolines Bioorg Med Chem Lett 2005 5 5030 5034 Ruhoglu O Ozdemir Z Calis U Gumusel B Bilgin AA Synthesis of and pharmacological studies on the antidepressant and anticonvulsant activities of some 1,3,5-trisubstituted pyrazolines Arzneimittelforschung 2005 55 431 436 Sahoo A Yabanoglu S Sinha BN Ucar G Basu A Jayaprakash V Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies Bioorg Med Chem Lett 2010 20 132 136 Steru L Chermat R Thierry B Simon P The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology (Berl) 1985 85 367 370 Thase ME The role of monoamine oxidase inhibitors in depression treatment guidelines J Clin Psychiatry 2012 73 Suppl 1 10 16 Tripathi AC Upadhyay S Paliwal S Saraf SK An expeditious one-pot microwave facilitated versus conventional syntheses: In vivo biological screening and molecular docking studies of some 3,5-disubstituted-4,5-dihydro-(1H)-pyrazole derivatives Med Chem Res 2016 25 390 406 Upadhyay S Tripathi AC Paliwal S Saraf SK 2-Pyrazoline derivatives in neuropharmacology: synthesis, ADME prediction, molecular docking and in-vivo biological evaluation EXCLI J 2017 16 628 649 Vogel HG Drug discovery and evaluation: pharmacological assays 2002 2nd ed. Berlin Springer-Verlag Volz HP Gleiter CH Monoamine oxidase inhibitors. A perspective on their use in the elderly Drugs Aging 1998 13 341 355 Willner P Mitchell PJ The validity of animal models of predisposition to depression Behav Pharmacol 2002 13 169 188 Youdim MB Edmondson D Tipton KF The therapeutic potential of monoamine oxidase inhibitors Nat Rev Neurosci 2006 7 295 309 Zeller EA Barsky J In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine Proc Soc Exp Biol Med 1952 81 459 461 Comparative study of physicochemical properties of synthesized 1,3,5-trisubstituted-2-pyrazoline derivatives (5a-5t) Data showing antidepressant, anti-anxiety and neurotoxicity studies of the synthesized 2-pyrazoline derivatives (5a-5t) <italic>In silico</italic> prediction of binding affinity (Glide gscore) and ADME parameters of the synthesized 1,3,5-trisubstituted-2-pyrazoline derivatives (5a-5t) <italic>In silico</italic> toxicity prediction data of the synthesized 1,3,5-trisubstituted -2-pyrazoline derivatives (5a-5t) Synthesis of 1,3,5-Trisubstituted-2-pyrazoline derivatives (a) Anti-anxiety activity (Number of entries in closed arms in Elevated Plus Maze Test); (b) Anti-anxiety activity (Time spent in closed arms in Elevated Plus Maze Test); (c) Antidepressant activity (Forced Swim Test); (d) Antidepressant activity (Tail Suspension Test) Ligand receptor interaction diagram of compound 5b at the binding site of MAO-A protein (PDB ID: 2Z5X) showing best anti-anxiety activity. (a) 2D Ligand receptor interaction diagram. (b) 3D Ligand receptor interaction diagram. Ligand receptor interaction diagram of compound 5k at the binding site of MAO-A protein (PDB ID: 2Z5X) showing best antidepressant activity. (a) 2D Ligand receptor interaction diagram. (b) 3D Ligand receptor interaction diagram.